One interpretation is that GLP-1 medications may weaken the extent to which established risk factors like impulsivity translate into harmful behavior
In a 13-week repeated dose toxicity study, SAG did not cause any neurobehavioral changes or adverse effects on hematology, blood biochemistry, urinalysis and other indicators at the highest dose of 1500 mg/kg/day
Using both together produces a much bigger GH pulse than either one alone
Most often, these side effects typically occur during the initial weeks of treatment and may improve over time as the body adjusts to the medication
The American Association of Clinical Endocrinologists/American College of Endocrinology consensus statement also recommends either a GLP-1RA or SGLT2i as a preferred treatment option (either as first-line or, more typically, second-line treatment after metformin) over alternative options such as a dipeptidyl peptidase-4 inhibitor, a thiazolidinedione (TZD), or a sulfonylurea (SU), for patients with T2D and ASCVD, stage 3 CKD, or heart failure with reduced ejection fraction [2]